FDA-cleared profile

MR 5300 and MR 7700 R11 MR Systems

Philips Medical Systems Nederlands B.V. · MRI · FDA-cleared (510(k))

Authorized purpose: The MR 5300 and MR 7700 R11 systems produce cross-sectional MR images, spectra, and derived parameters of the head, body, and extremities for interpretation by trained physicians and support labeled interventional MR-fluoroscopy workflows with compatible instruments selected and evaluated by the clinical user.

Clinical role
MRI acquisition, reconstruction, review, and release-specific workflow support.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The MR 5300 and MR 7700 R11 systems produce cross-sectional MR images, spectra, and derived parameters of the head, body, and extremities for interpretation by trained physicians and support labeled interventional MR-fluoroscopy workflows with compatible instruments selected and evaluated by the clinical user.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
  • Who uses it?Intended users: Qualified MRI technologists and physicians trained in magnetic resonance imaging.
  • What does the software produce?Output: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
  • What is its most important limitation?Key limitation: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

Clinical takeaway. Clinical role: The MR 5300 and MR 7700 R11 systems produce cross-sectional MR images, spectra, and derived parameters of the head, body, and extremities for interpretation by trained physicians and support labeled interventional MR-fluoroscopy workflows with compatible instruments selected and evaluated by the clinical user.

Evidence takeaway. Evidence from the reviewed source record: The K223442 FDA decision summary describes the MR 5300 and MR 7700 R11 systems, MR image and spectroscopy outputs, DICOM communication, release-specific software, and verification and validation. It emphasizes that physical-parameter accuracy and interventional MR use require clinical-user validation; it does not establish a general AI diagnostic sensitivity or specificity claim.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The MR 5300 and MR 7700 R11 systems produce cross-sectional MR images, spectra, and derived parameters of the head, body, and extremities for interpretation by trained physicians and support labeled interventional MR-fluoroscopy workflows with compatible instruments selected and evaluated by the clinical user.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
MRI acquisition, reconstruction, review, and release-specific workflow support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Hospital and outpatient MRI departments operating the cleared field strength, coils, protocols, and accessories.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified MRI technologists and physicians trained in magnetic resonance imaging.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The K223442 FDA decision summary describes the MR 5300 and MR 7700 R11 systems, MR image and spectroscopy outputs, DICOM communication, release-specific software, and verification and validation. It emphasizes that physical-parameter accuracy and interventional MR use require clinical-user validation; it does not establish a general AI diagnostic sensitivity or specificity claim.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The K223442 FDA decision summary describes the MR 5300 and MR 7700 R11 systems, MR image and spectroscopy outputs, DICOM communication, release-specific software, and verification and validation. It emphasizes that physical-parameter accuracy and interventional MR use require clinical-user validation; it does not establish a general AI diagnostic sensitivity or specificity claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K223442 FDA performance package for MR 5300 and MR 7700 R11 MR Systems

  • DesignManufacturer MR hardware, software, image-quality, physical-parameter, DICOM, safety, EMC, and usability verification and validation submitted in K223442
  • PopulationHead, body, extremity, spectroscopy, and labeled interventional MR workflows using the cleared MR 5300 or MR 7700 R11 configuration, coils, sequences, and instruments
  • Scopeexact submission
  • Tested versionMR 5300 and MR 7700 R11 MR Systems (K223442)
  • IndependenceSponsor or vendor study

K223442

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
3 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K223442. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-1214-2026 is Open, Classified for Upgrade to MR 7700. Product Code (REF): 782130. MR systems with SW version R11.1 and R12.1.. FDA reason: The potential for stiffness value errors when viewing exported MR Elastography (MRE) stiffness maps to viewer Picture Archiving and Communication System (PACS). FDA action: Philips began notification of consignees on about 12/03/2025 via mailed Urgent Medical Device Correction letter, with a corrected notification sent on about 12/18/2025. Consignees were instructed to identify if any affected units were on hand, that the systems could continue to be use in accordance with their intended use. They were asked to provide the notification to all users of the device for awareness, maintain the Urgent Medical Device Correction letter with affected systems until the software upgrade is installed, and complete and return the provided response form. A Philips representative will contact each consignee to schedule time for a Field Service Engineer (FSE) to install a software upgrade to resolve the issues beginning in January 2026 (reference FCO78100585, FCO78100620). FDA recall Z-2213-2025 is Open, Classified for MR 5300 Model Numbers (REF): (1) 782110, (2) 782135 (China ONLY), (3) 782152;. FDA reason: The potential for component failures in the Gradient Coil of the affected MR systems may act as a heat source with a potential to produce smoke and/or fire. FDA action: On June 30, 2025, URGENT MEDICAL DEVICE CORRECTION letters were sent to customers. 4. Actions that should be taken by the customer / user in order to prevent risks for patients or users 4.1. When using any affected system identified according to the information in section 3, follow the instructions below. 4.2. Pay particular attention if a scan interruption occurs and a scan abort symbol is encountered, which may appear in the user interface (UI) with the symbols shown in Figure 4 below: Figure 4. Scan Abort Symbols 4.3. When scan aborts occur the symbol is shown and applicable messages are presented in the message box (see Figure 5 and Figure 6 examples) 4.3.1. Check the status of the error messages in the User Interface (UI) screen. Click to expand the message box in case previous messages are hidden, see orange box in Figure 5 and Figure 6 below. If possible, correct the issue that is relevant to the error shown and continue scanning, for example: RF door must be closed while performing scan. Scan aborted. Patient support is moved while scanning, scan stopped. Coil A (or B) failure, coil disconnected? . 4.3.2. If, after a scan abort, one of the following conditions occur five times in a row stop scanning immediately and contact Philips Service to describe the problem: If there is no error message in the message box If the error message meaning is not clear 4.3.3. If the error message Gradient amplifier Rack Fault is received two times in a row, or if the error message Gradient amplifier Rack Fault is preceded or followed by an aborted scan with no message, then stop scanning immediately and contact Philips Service to describe the problem. 4.3.4. If you encounter any of these conditions described in 4.3.2 or 4.3.3 do not attempt any additional/further scans, including without limitation do not attempt any phantom scanning until your system has been... FDA recall Z-1804-2025 is Open, Classified for Product Name: MR 5300; Model Numbers: (1) 782110, (2) 782152;. FDA reason: Potential for alignment errors in the cross reference line functionality when reviewing images generated with the MobiView application. FDA action: On May 12, 2025 URGENT MEDICAL DEVICE CORRECTION letters were sent to customers. Actions that should be taken by the customer / user in order to prevent risks for patients or users You may continue to use your system(s) in accordance with the intended use. A. To avoid the potential issue of an incorrect cross reference line in MobiView generated images, use the same voxel size and field of view across all station scans. B. Do not use cross reference line functionality in box mode, all slices mode, or 3D mode. Use the cross reference line functionality in single slice mode. Circulate this notice to all users of this device so that they are aware of the issues and associated hazard/harm. Please retain this Urgent Medical Device Correction letter with your system(s) until the software upgrade is installed; ensure the notice is in a place likely to be seen/viewed. Please complete and return the attached response form to Philips MR promptly and no later than 30 days from receipt of this letter via email to: Philips.Recall@Philips.com. Completing this form confirms receipt of the Urgent Medical Device Correction letter, understanding of the issues, and required actions to be taken. 5. Actions planned by Philips MR to correct the problem A Philips representative will contact you to schedule time for a Field Service Engineer (FSE) to install a software upgrade to resolve the issues (reference FCO78100566, FCO78100584, FCO78100585, FCO78100620, FCO78100621). If you need any further information or support concerning this issue, please contact your local Philips representative. For North America, contact the Customer Care Solutions Center (1-800-722-9377, 8AM-8PM EST, Monday-Friday). This notice has been reported to the appropriate Regulatory Agencies. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program...
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-1214-2026

Open, Classified

2026-01-29

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

recall: Z-2213-2025

Open, Classified

2025-07-30

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

recall: Z-1804-2025

Open, Classified

2025-05-16

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems

  2. Routing

    Source context, not route validation: Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

    Scope: Product family. Current vendor materials are product-family evidence for K223442; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems · Philips MR 5300 and MR 7700 family context

  3. AI processing

    Source context, not route validation: Installed MRI hardware and release-specific scanner software with licensed coils, sequences, reconstruction options, and accessories.

    Scope: Product family. Current vendor materials are product-family evidence for K223442; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems · Philips MR 5300 and MR 7700 family context

  4. Returned objects

    Source context, not route validation: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed MRI hardware and release-specific scanner software with licensed coils, sequences, reconstruction options, and accessories.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223442; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223442; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Training
Only qualified mri technologists and physicians trained in magnetic resonance imaging should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223442; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K223442 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223442
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-12-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 3 FDA recall candidates were manually reviewed: 3 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 3 postmarket candidate records; 3 have been reviewed (3 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

11 sources - 3 history items

Source ledger

  1. FDA 510(k) decision summary K223442: MR 5300 and MR 7700 R11 MR Systems

    U.S. Food and Drug Administration - Published 2026-09-03 - Accessed 2026-09-03

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-1214-2026: Upgrade to MR 7700. Product Code (REF): 782130. MR systems with SW version R11.1 and R12.1.

    U.S. Food and Drug Administration - Published 2026-01-29 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-2213-2025: MR 5300 Model Numbers (REF): (1) 782110, (2) 782135 (China ONLY), (3) 782152;

    U.S. Food and Drug Administration - Published 2025-07-30 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. FDA recall Z-1804-2025: Product Name: MR 5300; Model Numbers: (1) 782110, (2) 782152;

    U.S. Food and Drug Administration - Published 2025-05-16 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  6. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  7. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  8. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  9. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  10. Philips MR 5300 and MR 7700 family context

    Philips - Accessed 2026-09-03

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  11. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K223442 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history